SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes

INTRODUCTION: Cardiovascular disease (CVD) is two to five times more prevalent in diabetic patients and is the leading cause of death. Therefore, identification of novel therapeutic strategies that reduce the risk of CVD is a research priority. Clinical trials showed that reduction in the relative r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodrea, Judit, Saeed, Adar, Molnar, Agnes, Fintha, Attila, Barczi, Adrienn, Wagner, Laszlo J., Szabo, Attila J., Fekete, Andrea, Balogh, Dora B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853531/
https://www.ncbi.nlm.nih.gov/pubmed/35176041
http://dx.doi.org/10.1371/journal.pone.0263285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853531/
https://www.ncbi.nlm.nih.gov/pubmed/35176041
http://dx.doi.org/10.1371/journal.pone.0263285

Ejemplares similares